Calvin Goforth, PhD

Calvin Goforth, PhD
Calvin Goforth, PhD, VIC Founder and Chief Executive Officer, has extensive experience in start-up company development in founder, investor, board member, and executive roles. His experience encompasses intellectual property assessment, building strong development teams, raising private investment and government funding, and bringing products to market. He received a BS in Aerospace Engineering with Highest Honors from the University of Texas at Austin.
Find me on:

Recent Posts

The Genomic Revolution: Unveiling Personalized Medicine's Investment Potential

In healthcare, a paradigm shift is underway – one that promises to transform healthcare as we know it. The emergence of personalized medicine, fueled by groundbreaking advancements in genomics and diagnostics, can save...

FDA Breakthrough Device Designation for High Impact Medical Devices

Within the VIC Tech portfolio, SFC Fluidics and Solenic Medical have both announced FDA Breakthrough Device designation. But what is FDA Breakthrough Device designation and what benefits does it provide? From a...

The Advantages of Investing in Venture Creation Firms Like VIC Tech

In the world of early stage investing, traditional venture capital funds have long been the go-to option for investors seeking exposure to high-growth opportunity companies. However, a different investment model is...

Due Diligence for Life Science Investments

Investing in a life science startup can be a lucrative opportunity, but it requires careful evaluation to weigh the potential reward against the level of risk. Members of VIC Tech's affiliated VIC Investor Network...

A Letter from our CEO

As CEO of VIC Tech, I am fortunate to have the opportunity to review exciting new life science technologies on an ongoing basis and regularly speak with life science thought leaders, inventors, investors, and large...

Our Life Science and Healthcare Future

Dramatic life science advancements are emerging that are likely to transform healthcare over the next 20 years. For example, continued rapid progress of cell and gene therapies will offer a complete cure for a wide...

Individual Investor Access to VC Stage Investments

In my last article, I discussed why individual investors should include privately held, innovation-driven companies in a diversified and balanced investment strategy [Seven Reasons Venture Capital-Stage Companies Should...

Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio

We live in eventful times. The world is changing at a dizzying pace…inflation, war and geopolitical instability, climate change, the pandemic, and supply chain issues are just a few of the important change factors. And...

SAFE vs. Convertible Notes: Which is a Better Choice for Early-Stage Investments?

Experienced early-stage investors are familiar with convertible note investments, which have evolved slightly but have been around in largely the same form for more than two decades. Convertible note investments start...

Letter from the CEO

It has been a year and ten months since the World Health Organization declared COVID-19 a pandemic. Despite the continuing pandemic, VIC’s business has largely returned to normal albeit with increased remote work, more...


VIC Tech Announces New Class of Fellows
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
Solenic Medical, Inc. Announces $5.1M Series A Funding Round Led by Johnson & Johnson Innovation – JJDC, Inc.
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.